Image For Activity Cover
April 26, 2022 - ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.
First time users

First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

Support Center Hours: Monday- Friday 9:00 am - 5:00 pm Eastern Time 

Description

ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

April 26th, 2022

11:00am-12:00pm ET

www.acmgeducation.net

 

Course Description

Challenges of implementing multiomics analysis into clinical care – case vignettes from the molecular tumor board at NCT Heidelberg.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Agenda

Presentations followed by live Q&A. 

Learning Objectives

At the conclusion of this session, participants should be able to:

 

  1. Describe how to approach complex molecular datasets for clinical curation.
  2. Discuss the omics data in a molecular tumor board
  3. Evaluate the clinical significance of multiomics analysis
Planning and Faculty

Moderator:

Manuela Benary, PhD

Bioinformatician

Charité – Universitätsmedizin Berlin, Berlin, Germany

Presenter(s):

Peter Horak, MD, PhD

Medical Oncologist for Clinical Translation

National Center for Tumor Diseases, Heidelberg, Germany

 

I serve as the Deputy Head of the Department of Translational Medical Oncology at NCT Heidelberg and the German Cancer Research Center (DKFZ). Following my training in internal medicine, hematology, and medical oncology at the Medical University of Vienna, I did postdoctoral research at the Massachusetts General Hospital Cancer Center and Harvard Medical School. After several years practicing clinical oncology, I joined the Department of Translational Medical Oncology in 2016 to focus on the clinical impact of comprehensive molecular and functional characterization of individual tumors in the NCT/DKTK MASTER program. I am primarily interested the discovery, development and standardization of novel biomarkers from large molecular datasets and their translation into the medical decision-making process. During the last years, we established a clinical workflow of precision oncology for rare cancer patients, demonstrating the clinical benefit of a molecularly-stratified therapeutic approach. With regard to standardization efforts in precision oncology, I participate in national and international consortia concentrating on development of guidelines for translation of biomarker-stratified precision medicine to routine clinical care. My research projects include retrospective analyses of –omic and clinical outcome data for discovery of predictive biomarkers/signatures as well as the development of T-cell-based immunotherapies in specific subtypes of soft-tissue sarcomas. I have an ongoing interest in the clinical implementation and impact evaluation of novel methodologies in precision oncology workflows, including predictive immunotherapy signatures, proteomic and epigenetic datasets.

Veronica Teleanu, MD

Medical Oncologist Clinical Translation

National Center for Tumor Diseases, Heidelberg, Germany

 

I am a medical oncologist at the National Center for Tumor Diseases in Heidelberg where I joined the Translational Medical Oncology Team in 2019. My areas of interest are Molecular Tumor Boards and ultra-rare sarcomas where I care for patients in the outpatient clinic of the Sarcoma Service. Together with my colleagues, I am involved in several projects focusing on identification of molecular biomarkers in rare cancers using a multi-omics approach within the frame of the NCT/DKTK MASTER program and improving interpretation of molecular data for targeted therapies recommendations.   

I received my MD from the University of Cluj-Napoca in Romania and subsequently completed my training in hematology/oncology in Bucharest (RO) and at the University of Ulm in Germany, were I additionally gained expertise in cytogenetics of myeloid malignancies and served as deputy of the Cytogenetics Lab of the department.

Planning Commitee:

Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Alex Wagner, PhD
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP  

Accredited Continuing Education Information

CME Educational Credits:

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Credit Designation

The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.

Financial Disclosures

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

 

 

All of the relevant financial relationships listed for these individuals have been mitigated.

NAME

ROLE

RELATIONSHIP/ COMPANY

 

Planning Member

Presenter Panelist Moderator

Peer Reviewer

 

Manuela Benary, PhD

 

Nothing to Disclose.

Peter Horak, MD, PhD

 

 

Consultant: Platomics, Saphetor SA, Other: Roche Pharma AG

Jennifer Malinowski, PhD, MS

 

 

Nothing to Disclose.

Beth Pitel, MS, CG(ASCP)

 

 

Nothing to Disclose.

Jane Radford, MHA, CHCP

 

 

Nothing to Disclose.

Gordana Raca, MD, PhD, FACMG

 

 

Nothing to Disclose.

Veronica Teleanu, MD

 

 

Nothing to Disclose.

Alex Wagner, PhD

 

 

Nothing to Disclose.

 

Summary
Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered

© 2022 American College of Medical Genetics and Genomics. All rights reserved.

Powered By